PDF
Recommendations on the use of conjugate pneumococcal vaccine – 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults: Economic evidence supplementary appendix
Organization: Public Health Agency of Canada (PHAC)Published: 2023
A systematic review, de novo model-based economic evaluation, and a multi-model comparison were used as economic evidence to support decision-making for the use of 15-valent (PNEU-C-15) and 20-valent (PNEU-C-20) conjugate vaccines.
Resource Group:
Implementation Tool
Product Type: Guide
Clinics
Vaccine Preventable Diseases
Communicable Diseases
Pneumococcal Disease
Specific Populations
Adults
Product Type: Guide
Category:
Program Planning and Delivery,Clinics,Vaccine Preventable Diseases,Communicable Diseases,Pneumococcal Disease,Specific Populations,Adults Program Planning and DeliveryClinics
Vaccine Preventable Diseases
Communicable Diseases
Pneumococcal Disease
Specific Populations
Adults
Language:
English
LinkResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.